Malignancies Clinical Trial
Official title:
Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses of Various Formulations of PWT-143 in Healthy Subjects
This single center first in human (FIH) study will comprise 2 parts; Part 1 will consist of 3
sequential dose groups (Groups A, B and C) and Part 2 will consist of 1 dose group (Group A).
There will be an option to include 2 additional dose groups in Part 1 (Groups D and E) to
assess alternative dose levels or formulations, if required.
In each study part, each subject will receive a single dose of investigational medicinal
product PWT-143 in each of 2 study periods (total of 2 single doses).
This first-in-human study will comprise 2 parts. In each part, each subject will receive a
single dose of investigational medicinal product (IMP) in each of 2 study periods (total of 2
single doses).
Part 1 (Single Ascending Dose) This is an open-label, single dose design. It is planned to
enroll up to 3 sequential groups (Groups A, B and C), comprising 3, 6 and 6 subjects,
respectively, with 2 optional additional groups (Groups D and E), each comprising 6 subjects,
to assess alternative dose levels or formulations (described below), if required.
The starting dose, dose increments and dose range are based on available pre-clinical data.
Current planned dose levels are: 10, 30, 60, 90 and 150 mg (dose levels 1, 2, 3, 4 and 5,
respectively); however, doses above 10 mg will be selected based on a review of emerging data
from this study.
It is planned to use Formulation 1 for dose administration in Part 1 (Group A), selected from
3 test formulations. However, based on the exposure seen in the emerging data, an alternative
formulation may be selected for dose comparison or escalation.
Part 2 (Food Effect Assessment) This is an open-label, randomised, single dose, 2-way
crossover design to assess a selected formulation of PWT-143 in the fed and fasted states.
Subjects will be administered a single dose of investigational medicinal product in the fed
and fasted states across 2 study periods according to the randomisation schedule. There will
be a minimum washout period for PWT-143 of 7 days between dose administrations in Periods 1
and 2.
It is planned that 1 group comprising 8 subjects will participate in Part 2. Subjects will be
considered evaluable if they have received both treatments (ie, fed and fasted) and have
completed safety assessments and PK sampling up to 24 h post-dose.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Completed |
NCT03236857 -
A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
|
Phase 1 | |
Completed |
NCT03005782 -
Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers
|
Phase 1 | |
Not yet recruiting |
NCT05602103 -
Cancer Therapy-related Cardiac Dysfunction Occuring in Children Treated by Anticancer Drugs for Malignancies
|
||
Terminated |
NCT00329329 -
Study of Satraplatin With Capecitabine to Treat Advanced Solid Malignancies
|
Phase 1 | |
Completed |
NCT00316511 -
Study of L-NDDP (Aroplatin) in Patients With Advanced Solid Malignancies or B-Cell Lymphoma
|
Phase 1 | |
Withdrawn |
NCT05253105 -
A Clinical Study of TAB006 in Patients With Previously Treated, Advanced Malignancies
|
Phase 1 | |
Completed |
NCT01407380 -
Study of PWT33597 Mesylate in Subjects With Advanced Malignancies
|
Phase 1 | |
Completed |
NCT01404728 -
Longitudinal Evaluation Study of Vaginal Stenosis With and Without Pelvic Radiation Therapy
|
N/A | |
Active, not recruiting |
NCT03678883 -
9-ING-41 in Patients With Advanced Cancers
|
Phase 2 | |
Not yet recruiting |
NCT05929495 -
Phase 2, Open-label, Single-arm Study on the Use of Metformin as Adjunctive Therapy in High-grade Glioma
|
Phase 2 | |
Completed |
NCT02257476 -
Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT00320827 -
Study of CS-1008 in Patients With Advanced Solid Malignancies and Lymphomas (Without Leukemic Component)
|
Phase 1 |